It was only with the use of Ab therapies, however, that hormonal FABP4 was clearly identified as having a robust role in metabolic diseases, as Abs cannot enter cells and cannot pass the blood-brain barrier to act within the CNS (50). This evidence concerns the gene FABP4 and metabolic disease.